Trial Profile
EffiXane non-interventionell study to determine safety and efficacy of nab-Paclitaxel (Abraxane) + Gemcitabin in first-line treatment of metastatic pancreatic cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 May 2019
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors ClinAssess
- 19 Dec 2017 Status changed from recruiting to completed.
- 15 Sep 2016 New trial record